February, 04 2016
The construction works for the new production plant of Stevanato Group officially started today at Sete Lagoas (Minas Gerais) in Brazil, with the traditional groundbreaking ceremony, at the presence of local Authorities and company management. The Group located in Piombino Dese (Padua - Italy) is specialized in the production of glass pharamaceutical primary packaging, in the technology for the development of glass tube forming machines, visual inspection machines, assembly and packaging machines, serialization solutions.
The new production plant in Sete Lagoas – with an investment of about 30 million Euro – will be located on a land of 40 thousand square meters (about 12 thousand square meters of building); and will host at full speed 15 last generation production lines (always developed and produced by the Group itself) for cartridges and ampoules production. It will employ about 200 people, that will be trained in the other plants of the Group. The plan is that the plant becomes operative at the beginning of 2017.
The Group continues its internationalization project that aims to cover the market worldwide and to increase production capacity, in order to locally supply pharmaceutical markets with the same quality level and customer support. Brazilian plant will increase the actual number of 9 production plants of the Group, located in Italy, Denmark, Slovakia, Mexico and China.
“The decision to realize a production plant in this Country has been taken after a detailed market analysis. Brazil is the sixth most important pharmaceutical market in the world and it is expected that it will continue to grow with a double-digit growth – explains Marco Stevanato, Vice President of Stevanato Group.– The expansion of this market in the future years will be linked to a general improvement of socio-economic conditions and to an increase of public and private health expenditure. The construction of the new plant, producing cartridges and ampoules for pharmaceutical use, will allow us to strengthen the partnership with the pharmaceutical companies operating in Brazil that are already our customers but also to increase our presence providing our products to the new players that are now facing this market”.